PLX-51107 by Plexxikon for Graft Versus Host Disease (GVHD): Likelihood of Approval
PLX-51107 by Plexxikon for Graft Versus Host Disease (GVHD): Likelihood of Approval
PLX-51107 is under clinical development by Plexxikon and currently in Phase II for Graft Versus Host Disease (GVHD). According to GlobalData, Phase II drugs for Graft Versus Host Disease (GVHD) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. Smarter leaders trust GlobalData The gold standard of business intelligence. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. PLX-51107 overview PLX-51107 is under development for the treatment of chronic lymphocytic leukemia, acute myeloid leukemia, graft versus host disease (GVHD), high-risk myelodysplastic syndrome (MDS) and myeloproliferative neoplasm. The drug candidate is a small molecule which acts by targeting BRD4. It is administered through oral route and parenteral route. It was also under development for the treatment of advanced malignancies, solid tumors, lymphoma, relapsed or refractory acute myeloid leukemia, high-risk myelodysplastic syndrome (MDS). Plexxikon overview Plexxikon, a subsidiary of Daiichi Sankyo Co Ltd, carries out the discovery and development of novel small molecule therapeutics to treat cancers. Its pipeline products portfolio includes pexidartinib indicated for the treatment of adjuvant glioblastoma, neoadjuvant breast, melanoma, and solid tumors; PLX7486 to treat pancreatic and solid tumors; PLX 9486 to treat the gastrointestinal stromal tumor and KIT-Mutant tumors; and PLX8394 to treat BRAF-Mutant tumors; PLX51107 against solid tumors, hematologic malignancies; PLX73086 addressing solid tumors. It conducts clinical trials to evaluate a novel drug or combination of drugs or the new use of a marketed drug. The company conducts research in collaboration with academic and clinical researchers to develop new drug therapies. Plexxikon is headquartered in South San Francisco, California, the US. For a complete picture of PLX-51107’s drug-specific PTSR and LoA scores, This content was updated on 11 March 2023 Give your business an edge with our leading industry insights. From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s . Smarter leaders trust GlobalData The gold standard of business intelligence.
Publish Date : 2023-11-19 01:22:21
Image and News Source : pharmaceutical_technology